Condition: Acute Promyelocytic Leukemia With PML-RARA · Sponsor: M.D. Anderson Cancer Center
This phase II trial studies how well tretinoin and arsenic trioxide with or without gemtuzumab ozogamicin works in treating patients with previously untreated acute promyelocytic leukemia. Drugs used in chemotherapy, such as tretinoin and arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotoxins, such as gemtuzumab ozogamicin, may find certain cancer cells and kill them without harming normal cells. Giving tretinoin and arsenic trioxide together with gemtuzumab ozogamicin may kill more cancer cells.
This description comes directly from the study's public registry record.
Farhad Ravandi-Kashani · 713-745-0394 · fravandi@mdanderson.org
Always discuss trial participation with your own doctor first.
| M D Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| MD Anderson Regional Care Center-Katy | Houston, Texas, United States | Recruiting |
| MD Anderson Regional Care Center-Bay Area | Nassau Bay, Texas, United States | Recruiting |
| MD Anderson Regional Care Center-Sugar Land | Sugar Land, Texas, United States | Recruiting |
| MD Anderson Regional Care Center-The Woodlands | The Woodlands, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01409161